nalgesin
actiofarma, uab - naproksenas - plėvele dengtos tabletės - 550 mg - naproxen
paracetamol/ibuprofen vale
vale pharmaceuticals limited - paracetamolis/ibuprofenas - infuzinis tirpalas - 10 mg/3 mg/ml - paracetamol, combinations excl. psycholeptics
daktarin
limedika, uab - mikonazolas - valgomasis gelis - 20 mg/g - miconazole
naldorex
limedika, uab - naprokseno natrio druska - plėvele dengtos tabletės - 550 mg - naproxen
myrelez
amdipharm limited - lanreotidas - injekcinis tirpalas užpildytame švirkšte - 60 mg - lanreotide
myrelez
amdipharm limited - lanreotidas - injekcinis tirpalas užpildytame švirkšte - 90 mg - lanreotide
myrelez
amdipharm limited - lanreotidas - injekcinis tirpalas užpildytame švirkšte - 120 mg - lanreotide
nalgesin forte
lex ano, uab - naprokseno natrio druska - plėvele dengtos tabletės - 550 mg - naproxen
migsun
orion corporation - sumatriptanas/naprokseno natrio druska - plėvele dengtos tabletės - 85 mg/500 mg - selective serotonin (5ht1) agonists
upstaza
ptc therapeutics international limited - eladocagene exuparvovec - amino rūgšties metabolizmas, įgimtos klaidos - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.